{"filing":{"accession_number":"0001193125-26-341315","cik":"0001622229","ticker":"COGT","company_name":"Cogent Biosciences, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"cogt-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-20260810.htm"},"events":[{"id":26403,"run_id":23994,"accession_number":"0001193125-26-341315","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"The filing discloses Cogent Biosciences' financial results for the second quarter ended June 30, 2026, via a press release attached as Exhibit 99.1. The disclosure includes condensed consolidated statements of operations showing Q2 2026 net loss of $96.4 million versus $73.5 million in Q2 2025, along with balance sheet data and detailed business highlights regarding clinical trial progress and regulatory milestones for bezuclastinib. This is a standard quarterly earnings release under Item 2.02.","company_name":"Cogent Biosciences, Inc.","ticker":"COGT","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27514,"accession_number":"0001193125-26-341315","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses Cogent Biosciences' financial results for the second quarter ended June 30, 2026, via a press release attached as Exhibit 99.1. The disclosure includes condensed consolidated statements of operations showing Q2 2026 net loss of $96.4 million versus $73.5 million in Q2 2025, along with balance sheet data and detailed business highlights regarding clinical trial progress and regulatory milestones for bezuclastinib. This is a standard quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T12:08:25.121504+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27514,"accession_number":"0001193125-26-341315","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses Cogent Biosciences' financial results for the second quarter ended June 30, 2026, via a press release attached as Exhibit 99.1. The disclosure includes condensed consolidated statements of operations showing Q2 2026 net loss of $96.4 million versus $73.5 million in Q2 2025, along with balance sheet data and detailed business highlights regarding clinical trial progress and regulatory milestones for bezuclastinib. This is a standard quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T12:08:25.121504+00:00","company_name":"Cogent Biosciences, Inc.","ticker":"COGT","filing_date":"2026-08-10"}]}